Conference Call Releases Heavy Information On The Research And Development Of New Coronal Mrna Vaccine

On the evening of November 9, PFE (NYSE: PFE) of the United States and biontech (Germany) announced that according to the preliminary analysis data of phase III clinical trial, the effective rate of the joint research and development of mRNA vaccine was as high as 90%, while the protection rate of ordinary influenza vaccine was only about 70%, which was far higher than the previous expectation, and it was much higher than the 50% required by FDA.

This major breakthrough news about the new crown vaccine caused market attention.

It is worth mentioning that the development partner of bio gene is a new vaccine partner in China. Affected by the news, on November 10, A-share Fosun Pharmaceutical (600196. SH) was trading at 56.66 yuan. Hong Kong shares of Fosun Pharmaceutical (02196. HK) once rose more than 20% and closed up 14.22%.

It is understood that in March this year, Fosun medicine was authorized by biontech to develop, register and commercialize Fosun new coronavirus vaccine (tentatively named "fubitai") based on its proprietary mRNA technology platform in mainland China, Hong Kong, Macao and Taiwan, and started clinical trials in China in July.

On the progress of mRNA vaccine, Fosun held a conference call at noon on November 10. Guo Guangchang, chairman of Fosun International (0656. HK), Wu Yifang, chairman of Fosun Pharmaceutical, Hui Aimin, President of Fosun global R & D center, and Qian Jiannong, chairman of Fosun lvwen (1992. HK), attended the conference.

What is the safety of the new RNA coronal vaccine? How long is the protection? What will be the output in the future? How will it be stored? The person in charge of Fosun medicine answered on the conference call.

It can be expected that the protection time of the new mRNA crown vaccine will be more than half a year

With regard to the 90% effective rate of the cooperative research and development of vaccines, Hui Aimin, President of Fosun global R & D center, said in a conference call that he was beyond expectations and was overjoyed that "vaccines that can achieve 90% protection level in history should also be very rare."

Hui Aimin explained that the standard set by the FDA of the United States and the regulatory authorities of other countries is that if the vaccine is developed and can protect 50% of the population, then it can be approved for marketing in this case. When the new mRNA crown vaccine was designed, the protection rate was 60%, and the protection rate of influenza vaccine every year was about 70%.

At the meeting, some investors were concerned about the protection time of bnt162b2, a candidate vaccine for mRNA crown.

Hui Aimin replied that half a year should be a relatively low indicator. There is no such data for long-term observation. According to some existing data, "I hope that our protection time exceeds the basic requirements and exceeds our expectation."

Hui Aimin explained that the protection time should be considered that after the antibody is produced, it will not disappear soon. Take the flu vaccine as an example. Although it is necessary to vaccinate once a year, it does not mean that the protection of influenza vaccine is less than one year, but that the influenza virus changes every year.

Hui Aimin said, "the protection period exceeds the minimum limit of half a year, which can be expected. But in the end, we have to wait for the data, and now we are just making some predictions."

The early or staged production pressure of mRNA new crown vaccine

According to Pfizer and biontech's current forecasts, it is estimated that up to 50 million doses of vaccine will be produced worldwide by 2020 and 1.3 billion doses by 2021.

So, how many 1.3 billion doses of vaccine will be supplied to China?

In a conference call on November 10, Wu Yifang, chairman of Fosun Pharmaceutical, said, "at the beginning, everyone needs vaccination, so no matter what, there will be periodic pressure on production capacity. Countries around the world will consider vaccination according to priority. " Wu Yifang said, "at present, we and biontech are also in-depth communication on the supply agreement, and the whole production capacity will be reasonably distributed around the world and among our major partners." If it is necessary to (also consider) carrying out capacity construction in China, "we are also actively communicating with the State Food and drug administration to specify the possible (there) construction methods and timetable in the future."

So, if bnt162b2, a new RNA coronal vaccine, is launched in China, how will Fosun and its partners distribute the economic benefits?

Wu Yifang, chairman of Fosun Pharmaceutical, said, "we will calculate the gross profit of the Chinese market according to the final pricing in the Chinese market and the cost of our production. If the gross profit is 65% for Fosun and 35% for biontech, all sales related expenses within 65% will be borne by Fosun."

How to ensure the cold chain transportation after the new mRNA crown vaccine comes into market in the future?

Wu Yifang, chairman of Fosun Pharmaceutical, stressed that Fosun has prepared the supply chain in an all-round way, and through communication with partner biontech, all details of the whole product in the process of transportation, storage and use have been clearly communicated. The current research shows that a thaw can be carried out in the middle of the product, and other studies are also in progress. "Currently, the most conservative cold chain conditions are used to ensure the quality of products."

?